News

New Zealand is reporting the first death of a person shortly after the vaccine was administered.

AstraZeneca’s combination of 2 long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 significantly.

In a head-to-head randomized controlled trial, 30% of outpatients who received convalescent plasma had disease progression, compared to 31.9% of patients who received placebo.

Public health guidance differed between countries in part because of a lack of relevant scientific evidence, resource limitations, and differing strategies, according to a new report.

The deaths occurred this month in Japan, and investigations into the deaths and the vaccine batches are ongoing.

A study from the United Kingdom shows the newer variant led to an increase in severe infections in a mostly unvaccinated population.

Here is a glimpse of the surge in incidence rates of the variant as it began to take hold in Mesa County, Colorado.

The Centers for Disease Control and Prevention (CDC) released data this week that showed greater breakthrough infections in a large study mainly compiled before the emergence of Delta as the predominant variant in the US.

The National Institutes of Health (NIH) announces single injection of monoclonal antibody against the Plasmodium mosquito-borne parasite prevented malaria throughout 9 month phase 1 trial.

Positive results of a phase 3 trial of Regeneron’s monoclonal antibodies treatment REGEN-COV among people at high risk for COVID-19 because of household exposure support the drug’s use for post-exposure prophylaxis.

Infection with hepatitis B (HBV) can be challenging. What will patients accept in exchange for the chance of a functional care?

An Israel study estimates vaccinated persons' risk of side effects including myocarditis, relative to the risk brought on by SARS-CoV-2 infection.

Rare cases of health care–associated meningitis and ventriculitis in adults caused by Candida species are associated with recent bacterial meningitis and broad-spectrum antibiotic use.

A new report says the public health officials within the Biden Administration are preparing for making the interim period closer together.

The submission comes day after BNT162b2 became the first fully approved COVID-19 vaccine by the FDA.

The company announced it filed its submission to prevent COVID-19 in individuals 18 years of age and older.

August is National Immunization Month. With the FDA’s approval of the Pfizer-BioNTech COVID-19 vaccine, providers will likely be having more conversations with patients on the topic. Motivational interviewing is an emerging strategy for providers to consider in their conversations with patients who are reluctant to get the vaccine.

Study comparing mRNA shots finds variability in response, though both generally safe and effective.

Attendance of professional and college football games may resume with COVID-19 mitigation measures, according to a study that found no association between games with limited attendance and COVID-19 cases.

David Weber, MD, MPH, explains what portion of the population may buy into the newly approved Pfizer-BioNTech vaccine.

Kevin J. Downes, MD, and Contagion® Section Editor Conan MacDougall, PharmD, MAS, BCPS, BCIDP, discuss these important topics as another season approaches.

With the full FDA approval of the Pfizer-BioNTech COVID-19 vaccine, Mark McClellan, MD, PhD, says more employer mandates will likely be coming, but he does not see federal government intervention in this area.

The most common adverse event was myocarditis, which was reported in nearly 500 patients. None of those patients had died as of the new analysis, and the rate per million cases was 3.5 cases.

The full approval for BNT162b2 will afford physicians greater prescribing capability, and will likely drive workplace vaccine mandates.

Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.

What does this form of pre-exposure prophylaxis (PrEP) mean in terms of options and initiation.

The decision on the final federal approval in the US could mean many more people would get the vaccine.

The World Health Organization (WHO) announces the Solidarity PLUS platform trial of drugs repurposed to treat COVID-19 after Solidarity trial candidates disappoint.

The study was supported by the National Institutes on Aging.